Discussion
Clarithromycin, a macrolide antibiotic, and nevirapine, a non-nucleoside reverse transcriptase inhibitor, are principally metabolised in the liver by the cytochrome P450 isoenzymes of the CYP3A family. The major presystemic active metabolite of clarithromycin is the R-epimer of 14-OH-6-0-methylerythromycin A. Clarithromycin is an inhibitor of CYP3A and its use in patients concurrently taking drugs metabolised by the cytochrome P450 system may be associated with elevations in their serum levels. Nevirapine acts as a mild to moderate enzyme inducer of CYP3A. It may therefore not only reduce plasma concentrations of other drugs metabolised by the same system but also acts as an autoinducer, with steady state reached after 7-9 days.
The principal side eVects of clarithromycin are gastrointestinal; however, less commonly, CNS side eVects have been reported, including dizziness, vertigo, anxiety, insomnia, tinnitus, confusion, disorientation, hallucinations, psychosis, and depersonalisation.
1 At the time of writing the Committee on Safety of Medicines (CSM)/Medicines Control Agency (MCA) have received 219 reports of suspected clarithromycin induced psychiatric disorders including psychosis (n=5), depersonalisation (n=5), and suicidal ideation (n=4) (CSM, personal communication). It has been postulated that macrolide antibiotics may cause a psychosis-like syndrome via their inhibitory action on glutamatergic neurotransmission in the brain.
2 Nevirapine has not been reported to cause serious CNS adverse eVects. In one study (n=18), concomitant administration of clarithromycin and nevirapine resulted in a 28% significant increase in nevirapine C min and a non-significant 26% increase in nevirapine area under the curve (AUC) and C max (24%), with no notable adverse eVects. There was also a significant reduction in clarithromycin AUC (30%) with a 58% significant Key messages + To raise awareness of the possibility of unexpected drug interactions between HAART and other more established drugs particularly with reference to cytochrome P450 induction/inhibition. + To raise awareness of the CSM/MCA/ MRC blue card HIV drug toxicity reporting scheme. + To be aware of drug interactions as a differential diagnosis in patients on HAART presenting with acute psychiatric syndromes.
increase in AUC of its active 14-OH metabolite.
3
A similar interaction study (n=15) confirmed these results although AUC increase of the active metabolite 14-OH clarithromycin was only 27%. 4 To date, the CSM/MCA have received no reports of suspected interactions between either zidovudine, didanosine or simvastatin and clarithromycin or nevirapine.
We therefore postulate that the accumulation of the active 14-OH metabolite of clarithromycin caused the acute neuropsychiatric reaction observed in our patient. The mechanism for this reaction is not clear.
Clarithromycin is frequently used in the treatment of bacterial respiratory tract infections and disseminated Mycobacterium avium complex infection in HIV positive individuals. We wish to alert physicians to the potential for interactions between established drugs with well documented side eVects, such as macrolide antibiotics, and the much newer classes of antiretroviral agents (ARVs) used in the treatment of HIV infection.
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